Aeterna Zentaris Inc.
https://www.zentaris.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aeterna Zentaris Inc.
New Drugs For Gastric Cancer, Liver Disease Among 14 Products Heading For EU Approval
Two orphan drugs are among a host of products that the European Medicines Agency’s human medicines committee has OKd for pan-EU approval.
Viking Plans To Go Directly To Phase III With Obesity Drug
In its Q2 earnings call, the biotech expressed optimism about developing VK2735 as a monthly injection, with an oral version moving into Phase II. An EOP2 meeting for its MASH drug is expected in Q4.
AbbVie’s Ex-Humira Immunology Business Is Booming
The company raised 2024 revenue expectations, driven by the second quarter performance of its Humira successors Skyrizi and Rinvoq.
Slimmer, Faster: Roche Aims To Speed Its Obesity Pill To Market
Roche is taking a more hard-nosed approach to portfolio prioritization, and said in its Q2 call that it believes it can move faster with a more slimmed down R&D pipeline.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice